The FDA has sent Novocure a not approvable letter for Optune Mya, its tumor treating fields system for brain metastases from non-small cell lung cancer. Novocure disclosed the letter on November 9. The agency cited uncertainty about the degree of clinical benefit and raised no safety concerns.

The premarket approval application rested on METIS, a randomized trial in 298 adults with one to 10 brain metastases after stereotactic radiosurgery. Median time to intracranial progression was 21.9 months with the device plus supportive care. Supportive care alone came in at 11.3 months, a hazard ratio of 0.67 with a p value of 0.016. The secondary endpoints went the other way, with no separation in overall survival, neurocognitive failure or radiological response on MRI.

Novocure plans to meet with the FDA to test whether approval is reachable without another study. Executive chairman William Doyle told investors in late October that the company expected a decision by year end and a launch in early 2027.

One positive surrogate endpoint with flat survival data is a thin file for a PMA, and this is the letter that usually follows it.